Pure Red-Cell Aplasia and Epoetin Therapy
2004; Massachusetts Medical Society; Volume: 351; Issue: 14 Linguagem: Inglês
10.1056/nejmoa040528
ISSN1533-4406
AutoresCharles L. Bennett, Stefano Luminari, Allen R. Nissenson, Martin S. Tallman, Stephen A. Klinge, Norene McWilliams, June M. McKoy, Benjamin Kim, E. A. Lyons, Steve Trifilio, Dennis W. Raisch, Andrew M. Evens, Timothy M. Kuzel, Glen T. Schumock, Steven M. Belknap, Francesco Locatelli, Jérôme Rossert, Nicole Casadevall,
Tópico(s)Blood groups and transfusion
ResumoBetween 1988 and 1998, antibody-associated pure red-cell aplasia was reported in three patients who had undergone treatment with recombinant human erythropoietin (epoetin). Between 1998 and 2000, 13 such cases were reported from France — 12 in patients who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neorecormon (a formulation of epoetin beta); both are products that are marketed outside the United States.
Referência(s)